INmune Bio Q3 net loss narrows to $6.5 mln, names new CEO

Reuters10-31

INmune Bio Q3 net loss narrows to $6.5 mln, names new CEO

Overview

INmune Bio Q3 net loss narrows to $6.5 mln from $12.1 mln year-over-year
Operating expenses for Q3 decreased to $7.4 mln from $12.3 mln year-over-year
Company announces leadership changes with David Moss as new CEO

Outlook

Company plans to file CORDStrom™ MAA submission mid-2026
Company expects End of Phase 2 meeting for XPro™ in Q1 2026
Final data on INKmune CARE-PC trial expected in Q4 2026

Result Drivers

CORDStrom MANUFACTURING - Successful completion of first two commercial pilot-scale manufacturing runs in preparation for regulatory filings
INKmune TRIAL PROGRESS - CARE-PC trial met primary endpoint and two secondary endpoints, indicating NK cell proliferation and function

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$6.47 mln
Q3 Basic EPS		-$0.24
Q3 Operating Expenses		$7.43 mln
Q3 Operating Income		-$7.43 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for INmune Bio Inc is $7.00, about 74% above its October 29 closing price of $1.82

Press Release: ID:nGNX6NVPqd

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2579177460?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 04:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579177460","market":"nz","top_or_hot":-1,"title":"INmune Bio Q3 net loss narrows to $6.5 mln, names new CEO","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>INmune Bio Q3 net loss narrows to $6.5 mln, names new CEO</title></head><body><p><span>Overview</span></p><ul><li><p>INmune Bio Q3 net loss narrows to $6.5 mln from $12.1 mln year-over-year</p></li><li><p>Operating expenses for Q3 decreased to $7.4 mln from $12.3 mln year-over-year</p></li><li><p>Company announces leadership changes with David Moss as new CEO</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company plans to file CORDStrom™ MAA submission mid-2026</p></li><li><p>Company expects End of Phase 2 meeting for XPro™ in Q1 2026</p></li><li><p>Final data on INKmune CARE-PC trial expected in Q4 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CORDStrom MANUFACTURING - Successful completion of first two commercial pilot-scale manufacturing runs in preparation for regulatory filings</p></li><li><p>INKmune TRIAL PROGRESS - CARE-PC trial met primary endpoint and two secondary endpoints, indicating NK cell proliferation and function</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$6.47 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.24</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$7.43 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$7.43 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/INMB\">INmune Bio Inc</a> is $7.00, about 74% above its October 29 closing price of $1.82</p></li></ul><p>Press Release: <span>ID:nGNX6NVPqd</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INmune Bio Q3 net loss narrows to $6.5 mln, names new CEO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINmune Bio Q3 net loss narrows to $6.5 mln, names new CEO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-31 04:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>INmune Bio Q3 net loss narrows to $6.5 mln, names new CEO</title></head><body><p><span>Overview</span></p><ul><li><p>INmune Bio Q3 net loss narrows to $6.5 mln from $12.1 mln year-over-year</p></li><li><p>Operating expenses for Q3 decreased to $7.4 mln from $12.3 mln year-over-year</p></li><li><p>Company announces leadership changes with David Moss as new CEO</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company plans to file CORDStrom™ MAA submission mid-2026</p></li><li><p>Company expects End of Phase 2 meeting for XPro™ in Q1 2026</p></li><li><p>Final data on INKmune CARE-PC trial expected in Q4 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CORDStrom MANUFACTURING - Successful completion of first two commercial pilot-scale manufacturing runs in preparation for regulatory filings</p></li><li><p>INKmune TRIAL PROGRESS - CARE-PC trial met primary endpoint and two secondary endpoints, indicating NK cell proliferation and function</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$6.47 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.24</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$7.43 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$7.43 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/INMB\">INmune Bio Inc</a> is $7.00, about 74% above its October 29 closing price of $1.82</p></li></ul><p>Press Release: <span>ID:nGNX6NVPqd</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nL1N3WB1MD:1","article_id":"2579177460","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579177460","pubTimestamp":1761856207,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"INmune Bio Q3 net loss narrows to $6.5 mln, names new CEOOverviewINmune Bio Q3 net loss narrows to $6.5 mln from $12.1 mln year-over-yearOperating expenses for Q3 decreased to $7.4 mln from $12.3 mln ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","INMB":"INmune Bio Inc"},"translate_title":"INmune Bio第三季度净亏损收窄至650万美元，任命新首席执行官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INMB":0.9},"content_text":"INmune Bio Q3 net loss narrows to $6.5 mln, names new CEOOverviewINmune Bio Q3 net loss narrows to $6.5 mln from $12.1 mln year-over-yearOperating expenses for Q3 decreased to $7.4 mln from $12.3 mln year-over-yearCompany announces leadership changes with David Moss as new CEOOutlookCompany plans to file CORDStrom™ MAA submission mid-2026Company expects End of Phase 2 meeting for XPro™ in Q1 2026Final data on INKmune CARE-PC trial expected in Q4 2026Result DriversCORDStrom MANUFACTURING - Successful completion of first two commercial pilot-scale manufacturing runs in preparation for regulatory filingsINKmune TRIAL PROGRESS - CARE-PC trial met primary endpoint and two secondary endpoints, indicating NK cell proliferation and functionKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$6.47 mlnQ3 Basic EPS-$0.24Q3 Operating Expenses$7.43 mlnQ3 Operating Income-$7.43 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for INmune Bio Inc is $7.00, about 74% above its October 29 closing price of $1.82Press Release: ID:nGNX6NVPqdFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive,dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579177460","isCrawlerRequest":true}